Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.

Thursday, the companies revealed Bavencio (avelumab) had failed to outdo chemo at extending the lives of second-line lung cancer patients with PD-L1-positive tumors. And the way Evercore ISI analyst Umer Raffat sees it, there’s no “good reason” to explain the flop.

Related Posts

• ‘Batman’ and ‘In Like Flint’ star, Jean Hale Coleman is dead ‘Batman’ and ‘In Like Flint’ star, Jean Hale Coleman has passed on at the age of 82. Jean who tussled between James Coburn’s character in the spy spo… Read More
• How a Targeted Drug Developed for Breast Cancer Is Helping People with Lung Cancer Paula Freitas has had many callings in her life: mother, anesthesia nurse, world traveler, ceramics artist, extreme sports enthusiast, and professional skydiv… Read More
• High burden of liver, stomach and cervical cancers among the Hispanic/Latino population  A new report shows that although Hispanic men and women in the continental United States and Hawaii have 25% to 30% lower overall cancer incidence and mor… Read More
• Nomadland actress, Melissa Yandell Smith dies of cancer at 64Melissa Yandell Smith, who played Frances McDormand's character's sister in Nomadland has died at the age of 64.Before her death, Melissa served as the Conserva… Read More
• High-intensity exercise regimen may boost active surveillance outcomes in prostate cancer Findings from the phase 2 ERASE trial suggest that men with localized prostate cancer undergoing active surveillance can increase their cardiorespiratory fitn… Read More